Abstract
Estrogen receptor (ER) expression was investigated by ER-immunocytochemical assay (ICA) and the dextran coated charcoal (DCC) method in 10 recurrent or primary-advanced breast cancer patients treated with endocrine or chmmo-endocrine therapy. In 6 of these 10 patients, ER was examined both before and after treatments by the 2 methods. ER contents measured by the DCC method were found to be decreased after treatments, however, no change in the immunoreactivities of ER-ICA was observed. In the remaining 4 patients, the ER of new lesions refractory to endocrine or chemo-endocrine therapy was examined. ER status was determined as negative in 3 of the 4 patients by the DCC method, whereas by ER-ICA, the proportion of ER stained cells was about 70 per cent, those cells being diffusely distributed in the section. A discrepancy between ER-ICA and the DCC method was thus demonstrated in breast cancer patients treated by endocrine therapy.
This is a preview of subscription content, log in via an institution to check access.
References
Koreman SG, Dukes BA. Specific estrogen binding by the cytoplasm of human breast carcinoma. J Clin Endocr 1970; 30: 639–645.
Jensen EV, Smith S, DeSombre ER. Hormone dependency in breast cancer. J Steroid Biochem 1976; 7: 911–917.
Nomura Y, Tashiro H, Shinozuka K. Changes of steroid hormone receptor content by chemotherapy and or endocrine therapy in advanced breast cancer. Cancer 1985; 55: 546–551.
Peetz ME, Nunley DL, Moseley HS, Keenan EJ, Davenport CE, Fletcher WS. Multiple simultaneous and sequential estrogen receptor values in patients with breast cancer. Am J Surg 1982; 143: 591–594.
Holdway IM, Bowditch JV. Variation in receptor status between primary and metastatic breast cancer. Cancer 1983; 52: 479–485.
King WJ, Greene GL. Monoclonal antibodies localize estrogen receptor in the nuclei of target cells. Nature (Lond) 1984; 307: 745–747.
King WJ, DeSombre ER, Jensen EV, Greene GL. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res 1985; 45: 293–304.
Shimada A, Kimura S, Abe K, Nagasaki K, Adachi I, Yamaguchi K, Suzuki M, Nagajima T, Miller LS. Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody. Proc Natl Acad Sci 1985; 82: 4803–4807.
Westphal HM, Mugele K, Beato M, Gehring U. Immunochemical characterization of wild-type and variant glucocorticoid receptors by monoclonal antibodies. EMBO J 1984; 3: 1493–1498.
Northrop JP, Gametchu B, Harrison RW, Ringold GM. Characterization of wild type and mutant glucocorticoid receptors from rat hepatoma and mouse lymphoma cells. J Biol Chem 1985; 260: 6398–6403.
Hull DF, Clark GM, Osborne CK, Chamness GC, Knight WA, McGuire WL. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43: 412–416.
Toi M, Hamada Y, Seto Y, Tanimoto M, Nakamura T, Toge T, Niimoto M, Hattori T. Immunocytochemical study on the variation in estrogen receptors of primary and nodal metastases of breast cancer. Jpn J Surg 1988; 18: 228–231.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Toi, M., Nakamura, T., Wada, T. et al. The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy. The Japanese Journal of Surgery 19, 768–772 (1989). https://doi.org/10.1007/BF02471732
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02471732